BR112018073786A2 - métodos e composições para tratamento de cânceres resistentes a inibidor da via de mapk não erk - Google Patents

métodos e composições para tratamento de cânceres resistentes a inibidor da via de mapk não erk

Info

Publication number
BR112018073786A2
BR112018073786A2 BR112018073786-0A BR112018073786A BR112018073786A2 BR 112018073786 A2 BR112018073786 A2 BR 112018073786A2 BR 112018073786 A BR112018073786 A BR 112018073786A BR 112018073786 A2 BR112018073786 A2 BR 112018073786A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
erk mapk
cancer
treating non
Prior art date
Application number
BR112018073786-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Saha Saurabh
WELSCH Dean
Decrescenzo Gary
James ROIX Jeffrey
Original Assignee
Biomed Valley Discoveries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries, Inc. filed Critical Biomed Valley Discoveries, Inc.
Publication of BR112018073786A2 publication Critical patent/BR112018073786A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
BR112018073786-0A 2013-12-20 2017-05-22 métodos e composições para tratamento de cânceres resistentes a inibidor da via de mapk não erk BR112018073786A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361919551P 2013-12-20 2013-12-20
US15/161,137 2016-05-20
US15/161,137 US20160317519A1 (en) 2013-12-20 2016-05-20 Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
PCT/US2017/033843 WO2017201532A1 (en) 2013-12-20 2017-05-22 Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers

Publications (1)

Publication Number Publication Date
BR112018073786A2 true BR112018073786A2 (pt) 2019-02-26

Family

ID=53403903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073786-0A BR112018073786A2 (pt) 2013-12-20 2017-05-22 métodos e composições para tratamento de cânceres resistentes a inibidor da via de mapk não erk

Country Status (15)

Country Link
US (5) US20160317519A1 (enExample)
EP (2) EP4653055A2 (enExample)
JP (3) JP7427212B2 (enExample)
KR (2) KR20230025941A (enExample)
CN (2) CN120501744A (enExample)
AU (3) AU2017267804B2 (enExample)
BR (1) BR112018073786A2 (enExample)
CA (1) CA3024703A1 (enExample)
CL (1) CL2018003282A1 (enExample)
IL (2) IL294056A (enExample)
MX (2) MX392121B (enExample)
RU (1) RU2018145048A (enExample)
SG (1) SG11201810287RA (enExample)
WO (2) WO2015095842A2 (enExample)
ZA (2) ZA201808480B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2890105C (en) 2012-11-01 2023-03-21 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
KR20180096621A (ko) * 2015-12-18 2018-08-29 이그니타, 인코포레이티드 암의 치료용 조합물
WO2017180817A1 (en) * 2016-04-15 2017-10-19 Musc Foundation For Research Development Treatment of septicemia and ards with erk inhibitors
CN109072311A (zh) * 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
US20210085663A1 (en) * 2017-05-16 2021-03-25 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
EP3700530B1 (en) * 2017-10-26 2023-04-19 Xynomic Pharmaceuticals, Inc. Crystalline salts of a b-raf kinase inhibitor
CN114366743A (zh) * 2018-04-09 2022-04-19 G1治疗公司 具有驱动致癌突变的癌症的治疗
CN110656172A (zh) * 2019-01-14 2020-01-07 南方医科大学珠江医院 一种预测小细胞肺癌对ep化疗方案敏感性的分子标志物及试剂盒
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
KR102697384B1 (ko) * 2022-01-13 2024-08-22 팔라디바이오텍 주식회사 리셉터 티로신 키나제 저해제를 탐색하는 방법
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021822A1 (en) 1993-03-19 1994-09-29 Sequenom, Inc. Dna sequencing by mass spectrometry via exonuclease degradation
US6140053A (en) 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US7439016B1 (en) 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
GB0320059D0 (en) 2003-08-27 2003-10-01 Solexa Ltd A method of sequencing
US7354939B2 (en) * 2004-05-14 2008-04-08 Vertex Pharmaceuticals Incorporated Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
US20090306020A1 (en) * 2005-05-27 2009-12-10 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
US8877436B2 (en) 2008-10-27 2014-11-04 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay on an automated platform
KR20120046018A (ko) 2010-10-04 2012-05-09 삼성테크윈 주식회사 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출
WO2012125848A2 (en) 2011-03-16 2012-09-20 Baylor College Of Medicine A method for comprehensive sequence analysis using deep sequencing technology
BR112015003418A2 (pt) * 2012-08-17 2017-07-04 Hoffmann La Roche produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica.
NZ630239A (en) * 2013-02-11 2017-08-25 Abraxis Bioscience Llc Methods of treating melanoma
MX2015010791A (es) * 2013-02-22 2015-11-26 Hoffmann La Roche Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX394252B (es) 2013-12-20 2025-03-21 Biomed Valley Discoveries Inc Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
WO2015095834A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2015095833A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2016025649A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a dot1l inhibitor and related methods
EP3250562B1 (en) * 2015-01-30 2024-11-27 Biomed Valley Discoveries, Inc. Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt
EP3250291B1 (en) * 2015-01-30 2020-08-26 Biomed Valley Discoveries, Inc. Crystalline c21h22c12n4o2 malonate

Also Published As

Publication number Publication date
JP7427212B2 (ja) 2024-02-05
MX392121B (es) 2025-03-21
ZA201808480B (en) 2022-04-28
CL2018003282A1 (es) 2019-10-18
MX2022005473A (es) 2022-06-02
AU2025204585A1 (en) 2025-07-10
US20190201387A1 (en) 2019-07-04
AU2023204587B2 (en) 2025-04-03
US20160317519A1 (en) 2016-11-03
IL263108B (en) 2022-08-01
EP3458056B1 (en) 2025-10-15
CN109475541A (zh) 2019-03-15
US20180104228A1 (en) 2018-04-19
SG11201810287RA (en) 2018-12-28
US11246859B2 (en) 2022-02-15
ZA202007734B (en) 2022-04-28
KR20230025941A (ko) 2023-02-23
EP3458056A4 (en) 2020-01-08
EP3458056A1 (en) 2019-03-27
IL294056A (en) 2022-08-01
AU2023204587A1 (en) 2023-08-17
US10881646B2 (en) 2021-01-05
WO2015095842A2 (en) 2015-06-25
MX2018014231A (es) 2019-05-15
RU2018145048A (ru) 2020-06-22
AU2017267804B2 (en) 2023-04-27
IL263108A (en) 2018-12-31
AU2017267804A1 (en) 2019-01-17
KR20190009804A (ko) 2019-01-29
CA3024703A1 (en) 2017-11-23
US20220117950A1 (en) 2022-04-21
WO2015095842A3 (en) 2015-08-20
JP2024133638A (ja) 2024-10-02
JP2019519519A (ja) 2019-07-11
US20210038587A1 (en) 2021-02-11
EP4653055A2 (en) 2025-11-26
WO2017201532A1 (en) 2017-11-23
JP2022034068A (ja) 2022-03-02
CN120501744A (zh) 2025-08-19

Similar Documents

Publication Publication Date Title
BR112018073786A2 (pt) métodos e composições para tratamento de cânceres resistentes a inibidor da via de mapk não erk
CO2020002588A2 (es) Composiciones que comprenden un inhibidor de shp2 y metodos para tratar el cáncer
BR112018012914A2 (pt) composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica
BR112015001690A2 (pt) mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
CY1121653T1 (el) C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης
BR112019005305A2 (pt) compostos espirocíclicos
MX2015005536A (es) Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.
CL2018002372A1 (es) Composiciones y métodos para tratar anemia (divisional solicitud 201503602)
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112015025944A8 (pt) composição compreendendo inibidores do caminho do hedgehog e uso dos referidos inibidores
BR112016006994A2 (pt) inibidores de erk e métodos de uso
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112022009631A2 (pt) Combinações de inibidores de dgk e antagonistas do ponto de checagem
BR112018007604A2 (pt) métodos para tratar câncer usando compostos de pirimidina e piridina com atividade inibitória de btk
BR112015000808A2 (pt) regime de dosagem para inibidores de janus quinase (jak)
BR112018007671A2 (pt) terapia de combinação para tratamento de malignidades
BR112018002550A2 (pt) mecanismo de resistência a inibidores do bromodomínio de bet
BR112016001781A2 (pt) inibidores de rorc2 e métodos de uso dos mesmos
BR112017021194A2 (pt) compostos espirocíclicos
BR112018004207A2 (pt) biomarcadores e métodos de tratamento de câncer
BR112017025698A2 (pt) composições e métodos para inibir a expressão do gene de hif2alfa
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]